Sucampo goes all-in on Amitiza with new DTC effort

Sucampo goes all-in on Amitiza with new DTC effort

The drugmaker is debuting a DTC campaign for the older constipation drug, despite a crowded therapeutic category and potential generics on the horizon.

Payers OK-ish with orphan drug prices

A survey shows fewer payers expect more restrictive policies in the near-term.

American Academy of Neurology releases opioid policy

The reveal comes days before hydrocodone products jump to a more restrictive access tier.

Five things for pharma marketers to know: Tuesday, September 30

Five things for pharma marketers to know: Tuesday, September 30

New Pfizer Viagra ads bring women into limelight; Open Payments database debuts to criticism; AbbVie/Shire deal set to be completed.

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

Late-stage immunotherapy results presented at a European medical conference over the weekend were heralded by clinicians, as AstraZeneca's lung-cancer darkhorse showcased strong early-stage results.

Pacira gets OPDP opioid promotion Warning Letter

Pacira gets OPDP opioid promotion Warning Letter

The FDA's Office of Prescription Drug Promotion says Pacira's promotional materials for Exparel are "extremely concerning," but the drugmaker tells investors the fuss is probably because opioids have been getting a lot of attention lately.

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Consumers modify mobile health devices

Mobile health devices may be more than they appear to be—consumers are taking an open-source approach to getting the monitors they want.

Five things for Pharma Marketers to know: Monday, September 29

Five things for Pharma Marketers to know: Monday, September 29

Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.

Five things for pharma marketers to know: Friday, September 26

Five things for pharma marketers to know: Friday, September 26

US government looks for alternative, nondrug, pain relief options for veterans; Gilead's HCV combo scores positive opinion in EU; FDA reopens commentary for social media draft guidance.

How the New Marketplace Will Affect Drug Access

How the New Marketplace Will Affect Drug Access

There are similarities between the 2014 formularies and their commercial counterparts. However, differences in the drug benefit designs show the predominance of four to five tiers, higher deductibles and higher copays or coinsurance levels compared to commercial benefits.

Five things for pharma marketers to know: Thursday, September 25

Five things for pharma marketers to know: Thursday, September 25

Shire pays $56-million fine to resolve improper ADHD marketing claims; FDA updates Chantix labeling to reflect new safety studies; GSK names new chairman.

FDA Social Media Guides Draw Industry, User Criticism

FDA Social Media Guides Draw Industry, User Criticism

Two FDA guidance documents on how health product manufacturers may participate in social media have each drawn criticism from affected industry and consumer groups.

Sanofi rolls out HCP software

Sanofi rolls out HCP software

MyStar Connect—available in Europe—translates glucose readings into actionable graphics.

Acorda's $525M Civitas buy opens Parkinson's pipeline

Acorda's $525M Civitas buy opens Parkinson's pipeline

The all-cash deal gives Acorda access to an experimental inhaled Parkinson's treatment that is meant to help patients when medication levels dip and symptoms surface.

NICE poised to turn down three ulcerative colitis drugs

Final guidance will float in around January, but the news puts Janssen and AbbVie on notice.

Advocates want FDA's Hamburg out

The reason: opioids.

Philips focuses on healthcare tech

Lightbulb company Royal Philips is swapping its heritage for the consumer healthcare business.

Five things for pharma marketers to know: Wednesday, September 24

Five things for pharma marketers to know: Wednesday, September 24

Pfizer tries to acquire Actavis; PhRMA says FDA social media rules are bad for consumers; US diabetes rates begin to slow.

US Treasury takes action on tax inversions

US Treasury takes action on tax inversions

The Treasury announced Monday it would eliminate certain techniques companies use to facilitate so-called tax inversions, which a number of drug companies have undertaken in the past six months.

MedImmune gets Fast Track nod

The drugmaker says the Phase-I monoclonal antibody has three distinct mechanisms of action.

OIG: Crack down on Medicare co-pay cards

The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.

Five things for pharma marketers to know: Tuesday, September 23

Five things for pharma marketers to know: Tuesday, September 23

Treasury Department takes action against corporate tax inversions; CDC pegs Ebola worst case scenario at 1.4 million infected by new year; NIH allocates $10 million in grants to increase female clinical trials.

OPDP slams cholesterol drug's e-mail claims

OPDP slams cholesterol drug's e-mail claims

The Office of Prescription Drug Promotion took aim at Cipher Pharmaceuticals and its marketer Kowa, in an Untitled Letter over an e-mail alert making what it said were unsubstantiated assertions.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Auxilium turns down Endo, leaves door open

Auxilium turns down Endo, leaves door open

The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.

Five things for pharma marketers to know: Monday, September 22

Five things for pharma marketers to know: Monday, September 22

GSK releases polio-infected water into Lasne River in Belgium; House reps Burgess and Schwartz introduce CME exemption bill for Sunshine Act; NIH and FDA announce plan to create facebook-esque catalogue of oral-drugs.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

FDA panel votes against taking drugs for "low-T"

FDA panel votes against taking drugs for "low-T"

An FDA advisory panel voted overwhelmingly against the use of testosterone-replacement drugs for "low-T" Wednesday, saying the label should narrow and that more safety information is needed.

Missing generic hurts Rite Aid

The drugstore chain has lowered its forecast, and generics are just one reason.

Novartis NY layoffs coming

Plans to unwind the Suffern, NY, site move forward this winter.

Merck's weekly DPP-IV on par with daily Januvia: study

Merck's weekly DPP-IV on par with daily Januvia: study

Merck unveiled the DPP-IV clinical trial results at the European Association for the Study of Diabetes Annual meeting Thursday.

Five things for pharma marketers to know: Thursday, September 18

Five things for pharma marketers to know: Thursday, September 18

FDA panel votes overwhelmingly against Low-T drugs; Stenda approved for fast-acting ED treatment; and Bayer hones life-sci focus, spins off material sciences business.

Rate of Sovaldi non-adherence points to need for patient support

Rate of Sovaldi non-adherence points to need for patient support

A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.

Endo makes $2.2B bid for Auxilium

Endo makes $2.2B bid for Auxilium

Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.

DOJ eyes Ranbaxy pricing

The Department of Justice is looking into Medicaid pricing.

Switzerland wants lower drug prices

Switzerland is pushing Roche to lower its prices on Perjeta

Five things for pharma marketers to know: Wednesday, September 17

HealthKit off to a bumpy start; Endo offers $2.2 billion for Auxilium; Gilead advanced pancreatic cancer drug fails in trial.

BMS striving to push Opdivo past Keytruda

BMS striving to push Opdivo past Keytruda

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one analyst.

Merck osteoporosis drug does not wow

Merck osteoporosis drug does not wow

Analysts do not expect odanacatib to be a major earner.

Regeneron's Eylea scores Breakthrough label

The designation is for diabetic retinopathy for patients with diabetic macular edema.

NY sues over Forest Alzheimer's medication

NY's attorney general alleges that a formulation switch is an attempt to create monopoly.

Six things for pharma marketers to know: Tuesday, September 16

Six things for pharma marketers to know: Tuesday, September 16

Allergan inches closer to Valeant takeover; Mylan trials underway for Lantus biosimilar and generic Advair; FDA advisers to make decision tomorrow on whether testosterone products are being prescribed correctly and if the drugs' label merits change.

AbbVie, Biogen to file MS drug next year

AbbVie, Biogen to file MS drug next year

Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Avonex (interferon beta-1a) on some measures among relapse-remitting MS patients.

Takeda backs Contrave with 900 sales reps

Takeda backs Contrave with 900 sales reps

Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to woo patients, physicians and payers.

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: Monday, September 15

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

To Expand Their Appeal, Children's Hospitals Need to Sharpen Their Focus

To Expand Their Appeal, Children's Hospitals Need to Sharpen Their Focus

To find stability, children's hospitals must offer value to today's more empowered healthcare consumers. This requires building strong relationships with moms—specifically millennial moms.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, September 12

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are expected to ship in 2015.

Field Notes: WPP's Stream Tackles Health Issues

Field Notes: WPP's Stream Tackles Health Issues

Stream Health, WPP's "unconference" which took place in Florida earlier this week, provided a diverse and large amount of content in a short amount of time.

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Nurses undeterred by internet bans at work: study

Nurses undeterred by internet bans at work: study

Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.

Merck's Keytruda is shipping

Merck's Keytruda is shipping

The first-in-class PD-1 was approved only last week.

Five things for pharma marketers to know: Thursday, September 11

Five things for pharma marketers to know: Thursday, September 11

EU grants Lilly/BI Lantus biosimilar approval; FDA approves Contrave weight-loss pill; Republicans take increased NIH funding off the table in Medical Innovation Act.

Opioid CME aims to alter prescribing, lift outcomes

Opioid CME aims to alter prescribing, lift outcomes

A series of CME initiatives, funded by Mallinckrodt, is designed to change opioid prescribing behavior.

CDC: children not receiving preventative care

CDC: children not receiving preventative care

A Centers for Disease Control and Prevention report indicates that following basic childhood care and prevention guidelines could catch health concerns before they become health problems that require costly medical services later in life.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.

Researcher ties corporate money to favorable drug reviews

The Milbank Quarterly has published a study that may put Sunshine skeptics on edge.

Industry wary of Apple Watch

The impact health monitors have on consumer habits and on patient-physician relationships has yet to be quantified.

GSK consumer division under scrutiny

A US investigation into GlaxoSmithKline has stirred up internal paperwork that the UK drugmaker was looking into compliance violations in its consumer division in 2012.

Five things for pharma marketers to know: Wednesday, September 10

Five things for pharma marketers to know: Wednesday, September 10

Auxilium slashes headcount by 30%; poll finds majority of voters support action against tax inversions; FDA panel votes 6-4 against Actavis-backed blood-pressure pill.

AbbVie ceded generic Tricor to protect AndroGel: FTC suit

AbbVie ceded generic Tricor to protect AndroGel: FTC suit

The FTC is suing AbbVie and two other firms in a pay-for-delay case that could have wider implications for pharma

The Planning Shop joins Omnicom

The London healthcare brand and research agency will be part of Omnicom's DAS Group.

Haymarket launches endocrinology HCP site

The new site, which includes professional resources on diabetes, debuted online and in app form today.

Novo seeks liraglutide obesity indication

Novo seeks liraglutide obesity indication

An FDA advisory panel will consider evidence supporting a weight-loss indication Thursday.

Everyday Health adds payer expert

The media company has added managed-markets expertise to its roster, bringing on the former head of IMS Health's global payer/provider division.

Five things for pharma marketers to know: Tuesday, September 9

Five things for pharma marketers to know: Tuesday, September 9

Mayo Clinic is reported to partner with Apple's iWatch for remote patient outreach; FTC sues AbbVie and Teva over pay for delay; JAMA study concludes that drugs given to patients with advanced dementia are not worth the price.

Monday Moves: September 8

Manufacturer, agency and consulting hires and promotions

BI Spiriva combo has Phase-III success

BI Spiriva combo has Phase-III success

The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."

Fail-fast doctrine ups late-stage success

Fail-fast doctrine ups late-stage success

Thomson Reuters finds the pharmaceutical industry is getting better at abandoning failures earlier.

Five things for pharma marketers to know: Monday, September 8

Five things for pharma marketers to know: Monday, September 8

BMS files patent suit over Merck's Keytruda; Purdue says reformulated Oxycontin curtails abuse; Lilly sues CMS over Alzheimer's disease diagnostic agent.

Changes at Your Local Pharmacy: Lessons in Bold Leadership

Changes at Your Local Pharmacy: Lessons in Bold Leadership

What's happening in the pharmacy business is a study in leadership, with important lessons for pharma

Five things for pharma marketers to know: Friday, September 5

Five things for pharma marketers to know: Friday, September 5

Gilead in talks to license Sovaldi in several countries, CMS gets over 800 comments requesting CME exemption, pharmacist tied to meningitis scare is arrested, Keytruda wins approval, RTC rebrands to Wunderman

IBM's Watson rolls out to wider healthcare market

IBM's Watson rolls out to wider healthcare market

@Point of Care has integrated IBM's much-touted Watson cognitive technology into its real-time clinical-decision platform

Lilly basal bests Lantus in T1D, despite safety concerns

Lilly basal bests Lantus in T1D, despite safety concerns

Lilly's long-acting insulin showed it's more effective in type 1 diabetics than Lantus, but concerns about its overall profile persist.

Merck scores first US PD-1 approval

Merck scores first US PD-1 approval

The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have taken Bristol-Myers Squibb's Yervoy (ipilimumab).

Drug spend will continue to rise through 2023

Drug spend will continue to rise through 2023

The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.

CDC: Every state has an obesity problem

The latest data shows an overall widening of the US.

FDA sanctions don't kill a business

Bloomberg reports that India's Wockhardt has become an M&A target.

Pfizer, Novartis ink respiratory deal

Pfizer will sell two Novartis drugs in the UK.

Five things for pharma marketers to know: Thursday, September 4

Five things for pharma marketers to know: Thursday, September 4

PD-1 inhibitor launches in Japan with a lofty price tag; more Zohydro pushback; J&J developing Ebola vaccine.

Brown leaves ICC Lowe, takes reins at indie network

Brown leaves ICC Lowe, takes reins at indie network

Brown has stepped down as general manager of the IPG network to lead the GuideMark Health agencies as CEO.

Google-backed Calico signs $1.5B marketing deal with AbbVie

Google-backed Calico signs $1.5B marketing deal with AbbVie

Google's independent biotech announced today it will enlist AbbVie in its mission to cure death.

Sanofi prices Cerdelga

Sanofi prices Cerdelga

The $310,000 price for the Gaucher disease medication is typical of the rare-disease category.

CVS changes name

Parent company CVS Caremark is changing its name to better reflect "its broader health care commitment."

Roche to lay off 100, restructure

Sales reps are among the pinked-slipped in Spain.

Five things for pharma marketers to know: Wednesday, September 3

Five things for pharma marketers to know: Wednesday, September 3

AbbVie inks agreement for oncology asset; largest single day med device recall on record; US appeals court revives Botox improper labeling/marketing case.

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low on doc awareness

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, September 2

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against Ebola; Novo Nordisk kills inflammatory business unit to shift resources to diabetes and obesity; generics firm Cipla could stand to gain from Advair patent expiry.

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, August 29

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Wearable Devices: Thinking Beyond the Backend

Wearable Devices: Thinking Beyond the Backend

With wearable technology, digital health has moved past content we can search, share and engage with to something far more personal—defining ourselves as the data that we track, analyze and share.

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the September 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.